Another new kinase targets troponin I.

report that protein kinase D (PKD), a serine kinase, phosphorylates the cardiac thin filament protein, troponin I (TnI). These investigators performed a detailed and complete set of experiments, initially noting the association of TnI and PKD, and then mapping the sites that PKD phosphorylates, Ser22 and Ser23. PKD treatment of myocytes was further demonstrated to result in desensitization of the myofilaments to calcium and accelerated isometric crossbridge cycling.1 Why is finding an additional kinase for TnI important? TnI is a critical component of the calcium switch of striated muscle, and the cardiac specific isoform is further specialized because of the presence of an amino-terminal region containing protein kinase A (PKA) sites. Troponin (Tn) consists of three subunits including TnI, the inhibitory component, which inhibits actin-myosin interactions at diastolic calcium levels, TnC, the calcium binding subunit, and TnT, which anchors Tn to tropomyosin (Tm) but also contributes to regulation of muscle activation. During systole, a regulatory Ca -binding site on TnC is occupied, increasing the affinity of TnC for TnI and lessening the interaction between TnI and actin-Tm. This results in movement of Tm-Tn on the thin filament, releasing the inhibition of actin-myosin interactions and increasing the probability of cycling of the crossbridge and muscle shortening (reviewed by Tobacman2). Studies conducted in the 1970s demonstrated TnI to be a target of PKA phosphorylation, and Solaro et al3 demonstrated the phosphorylation of TnI on administration of adrenaline to perfused hearts. Since that time, the specific sites of phosphorylation of PKA, PKG (also at PKA sites), PKC, p21–activated kinase (PAK), and now PKD have been elucidated.4–6 More importantly, the functional effects of site-specific phosphorylations have been discovered by using a variety of biochemical, structural, and physiological studies from molecular studies in vitro to whole animal physiology (reviewed by Metzger and Westfall7). As illustrated in the schematic of cardiac TnI (Figure), TnI is a small molecule that has multiple binding partners. Just as binding of regulatory Ca to TnC alters the affinity of binding between TnI and TnC, phosphorylation at the various sites influences interactions between the troponin complex and actin-Tm to regulate the contractile process. To understand the context of the article by Haworth et al,1 it is important to note that PKD is downstream from PKC, yet it phosphorylates TnI at the “PKA” sites. Numerous studies have indicated that phosphorylation of TnI at PKA and PKC sites have somewhat opposing effects. Phosphorylation at the PKA sites is associated with desensitization of the myofibrillar ATPase to Ca , augmenting the rate of relaxation enhancing crossbridge cycling and accelerating unloaded shortening velocity.8–14 In terms of structural studies, unphosphorylated TnI complexed with TnC has an extended conformation and thus has extensive contact throughout the molecule.15–17 Phosphorylation of TnI by PKA shrinks or collapses TnI structure and brings the N terminus in close proximity to the C terminus.18 All of these findings indicate a role for TnI in diastolic relaxation, a key effect of -adrenergic stimulation. More recent data however suggest TnI phosphorylation at PKA sites also has effects on myocyte power output,19 as well as systolic performance, force frequency relationship, and the response to afterload in vivo.20,21 Although phosphorylation by PKC has been less intensively studied, data indicate phosphorylation of TnI by PKC is associated with a decreased maximal myofibrillar MgATPase.22 The primary PKC phosphorylation sites of mouse TnI are Ser-42, Ser-44, and Thr-143; however, in vitro studies with site-specific mutants indicated that the Ser-42 and Ser-44 sites (referred to as Ser-43 and Ser-45 because of including the initiating methionine) are primarily involved in the functional effect.23 A recent in vitro study by Burkart et al24 suggests desensitization of sliding velocity is produced by PKC phosphorylation at the Thr-143 site; however, the proximal PKC sites of TnI had the dominant effect on tension-calcium relationships. Importantly, there is evidence that altered phosphorylation at specific TnI sites may be present in failing hearts. Zakhary et al25 demonstrated a 25% decrease in PKA phosphorylation of TnI in myocardium from patients with end-stage heart failure. This finding was supported by other studies.26–28 PKC phosphorylation of TnI may be increased in heart failure. Takeishi et al29 reported that transgenic mice overexpressing PKC isoform 2 have diminished cardiac function associated with increased TnI phosphorylation. This PKC isoform is also increased in expression in human heart failure. There is also indirect evidence that failing human heart myofilaments may have increased phosphorylation by PKC.30 Thus, in heart failure, the relative activities and localizations of PKA, PKC isoforms, and PKD, as well as the relevant phosphatases, may alter the balance of phosphorylation of specific sites on TnI that are functionally important. It should not be a surprise that dynamic regulation of the thin filament by phosphatases and kinases is more complex The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association. From the Division of Cardiology, Department of Pediatrics and Institute of Molecular Cardiobiology, Johns Hopkins University School of Medicine, Baltimore, Md. Correspondence to Johns Hopkins University School of Medicine, Ross 1144, 720 Rutland Ave, Baltimore, MD 21205. E-mail [email protected] (Circ Res. 2004;95:1043-1045.) © 2004 American Heart Association, Inc.